Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine and Irinotecan in Advanced Kidney Cancer
NCT00089102Phase 2Terminated
- Sponsor
- Medical University of South Carolina
- Start
- Sep 2003
- Primary completion
- Jul 2009
- Modality
- Nanoparticles, Monoclonal Antibodies, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of gemcitabine, irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab in renal cell carcinoma (RCC), sponsored by Medical University of South Carolina. Started Sep 2003; status: terminated.
02
Drugs
gemcitabineirinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT00089102.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00089102.